How can I differentiate osteoarthritis, rheumatoid arthritis, and gout, and what are the appropriate treatments for each?

Differentiating Osteoarthritis, Rheumatoid Arthritis, and Gout

These three conditions can be reliably distinguished using specific clinical patterns, joint distribution, laboratory markers, and imaging findings, with each requiring fundamentally different treatment approaches to prevent disability and preserve quality of life.

Clinical Differentiation

Osteoarthritis (OA)

OA presents with pain on usage and minimal morning stiffness (typically brief), affecting characteristic joints in an asymmetric pattern 1:

• Target joints: Distal interphalangeal joints (DIPJs), proximal interphalangeal joints (PIPJs), thumb base (first CMC), and index/middle metacarpophalangeal joints (MCPJs) 1
• Physical findings: Heberden nodes (DIPJs) and Bouchard nodes (PIPJs), bony enlargement, cool joints, lateral deviation of IPJs 1
• Demographics: Typically age >40 years, female predominance, associated with obesity and prior joint injury 1
• Symptoms: Pain worsens with weight-bearing and activity, only mild or absent morning stiffness 1
• Laboratory: Normal inflammatory markers; blood tests not required for diagnosis 1

Rheumatoid Arthritis (RA)

RA manifests as symmetric polyarthritis with prolonged morning stiffness (≥1 hour) and systemic features 1:

• Target joints: MCPJs, PIPJs, and wrists bilaterally; notably spares DIPJs 1
• Physical findings: Joint swelling with soft tissue inflammation, warm joints, symmetric distribution 1
• Systemic features: Fatigue, depression, subcutaneous nodules, potential extra-articular manifestations (interstitial lung disease, vasculitis, inflammatory eye disease) 1
• Laboratory: Positive rheumatoid factor (RF) and/or anti-citrullinated protein antibody (ACPA) in 70-80% of cases; elevated acute-phase reactants (ESR, CRP) 1
• Note: 30% may be seronegative, complicating diagnosis 2

Gout

Gout presents with acute, severe monoarticular or oligoarticular attacks, often with dramatic inflammatory signs 1:

• Target joints: First metatarsophalangeal joint (podagra) most common, but can affect knees, ankles, wrists; may superimpose on pre-existing OA 1
• Physical findings: Intense erythema, warmth, swelling, exquisite tenderness; chronic tophi in longstanding disease 1
• Laboratory: Elevated serum uric acid (though may be normal during acute flare); elevated CRP and leukocyte count during attacks 3
• Gold standard: Monosodium urate crystals on synovial fluid analysis 1
• Imaging: Double contour sign on ultrasound, periarticular tophi on CT/MRI 3, 2

Diagnostic Algorithm Using Four Key Parameters

A recent study demonstrated that gout can be differentiated from OA and CPPD with high sensitivity (95.1%) using just four clinical parameters 3:

1. Elevated uric acid (most discriminating factor)
2. Elevated CRP (indicates inflammatory process)
3. Presence of arterial hypertension (associated with gout)
4. Male sex (gout more common in men)

When these parameters are present, gout is highly likely; their absence favors OA 3.

Treatment Approaches

Osteoarthritis Management

Core treatments that must be offered to all OA patients include education, structured land-based exercise, and weight loss if overweight 1:

Non-pharmacological (First-line)

• Education about the condition to counter misconceptions that OA is inevitably progressive 1
• Structured exercise programs: Local muscle strengthening and general aerobic fitness 1
• Weight management: Essential for overweight/obese patients 1
• Assistive devices: Walking aids, joint supports, shock-absorbing footwear 1

Pharmacological (Stepwise approach)

1. First-line: Paracetamol/acetaminophen for pain relief (regular dosing) 1
2. Second-line: Topical NSAIDs for knee and hand OA 1
3. Third-line: Oral NSAIDs or COX-2 inhibitors at lowest effective dose with proton pump inhibitor for gastroprotection 1
4. Adjunct: Intra-articular corticosteroid injections for moderate-to-severe pain 1
5. Avoid: Glucosamine, chondroitin (not recommended) 1; opioids (strongly not recommended) 1, 4

Surgical

• Joint replacement: Consider when symptoms substantially affect quality of life and are refractory to non-surgical treatment; refer before prolonged functional limitation develops 1

Rheumatoid Arthritis Management

Early aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) is essential to prevent joint destruction and disability 1:

Treatment Strategy

• Goal: Complete disease remission or near-remission using treat-to-target approach 1
• Timing: Early referral to rheumatology and prompt DMARD initiation critical for outcomes 1
• Monitoring: Use composite disease activity scores (DAS28, SDAI, or CDAI) to guide treatment adjustments 1

Pharmacological

1. DMARDs: Early initiation (within weeks of diagnosis) is standard of care 1
2. Biologic response modifiers: For inadequate response to conventional DMARDs 1
3. NSAIDs/corticosteroids: For symptomatic relief only, not disease-modifying 1

Without aggressive DMARD therapy, 80% of RA patients are working at 2 years but only 68% at 5 years, with life expectancy shortened by 3-5 years 1.

Gout Management

All patients with tophaceous gout, radiographic damage, or frequent flares require urate-lowering therapy (ULT) with a treat-to-target approach 1:

Acute Flare Treatment (Strong recommendations)

• First-line options (choose one): Colchicine, NSAIDs, or glucocorticoids (oral, intra-articular, or intramuscular) 1
• Avoid: Aspirin and opioids 1

Urate-Lowering Therapy (ULT)

Strong recommendations for ULT initiation 1:

• Indications: Tophaceous gout, radiographic damage, or frequent flares (≥2 per year) 1
• First-line agent: Allopurinol (preferred over febuxostat) 1
• Starting dose: Low-dose allopurinol (≤100 mg/day, lower in chronic kidney disease stage ≥3) or febuxostat (<40 mg/day) 1
• Target: Serum uric acid <6 mg/dL using treat-to-target strategy with dose titration 1
• Flare prophylaxis: Mandatory concomitant anti-inflammatory prophylaxis (colchicine, NSAIDs, or low-dose glucocorticoids) for at least 3-6 months when initiating ULT 1
• Timing: Can initiate ULT during an acute flare 1

Refractory Disease

• Pegloticase: For patients with refractory tophaceous gout not responding to conventional ULT 1

Lifestyle Modifications

• Dietary changes: Limit purine-rich foods, alcohol (especially beer), and high-fructose corn syrup 1
• Weight loss: If overweight or obese 1
• Hydration: Adequate fluid intake 1

Critical Pitfalls to Avoid

1. Do not delay DMARD therapy in RA: Waiting for "definitive" diagnosis leads to irreversible joint damage 1
2. Do not use NSAIDs long-term in OA without gastroprotection: Always co-prescribe proton pump inhibitor 1
3. Do not stop ULT during acute gout flares: Continue ULT and treat flare separately 1
4. Do not start ULT without flare prophylaxis: This causes treatment-limiting flares 1
5. Do not assume seronegative arthritis excludes RA: 30% of RA patients are RF/ACPA negative 2
6. Do not rely solely on serum uric acid during acute gout: Levels may be normal during flares 1
7. Do not use opioids for OA pain management: Strongly not recommended due to poor risk-benefit ratio 1, 4